ArticleInfectious diseases now2022
Evolution of anti-SARS-CoV-2 immune response in a cohort of French healthcare workers followed for 7 months.
Article in Infectious diseases now, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04488484 (Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group), which is not on this map. Cited by 9 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group
Who cites it
9 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prevalence and symptoms of Long Covid-19 in the workplace.Occupational medicine (Oxford, England) · 2025Pooled it
- Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025Pooled it
- What is the impact of long-term COVID-19 on workers in healthcare settings? A rapid systematic review of current evidence.PloS one · 2024Pooled it
- Nucleocapsid Antibodies as an Optimal Serological Marker of SARS-CoV-2 Infection: A Longitudinal Study at the Thomayer University Hospital.Journal of clinical laboratory analysis · 2025Article
- Article
- Prevalence and risk factors of long covid and its associated adverse work outcomes among workers in the manufacturing sector in Malaysia - a mixed-methods study protocol.Journal of health, population, and nutrition · 2024Article
- Persistence of SARS-CoV-2 IgG Antibody Response among South African Adults: A Prospective Cohort Study.Vaccines · 2023Article
- SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to understand the immune response among healthcare workers (HCWs) following SARS-CoV-2 infection, and to determine the infection prevalence during the first wave of the pandemic among workers in our hospital.
methodsDetermination of the serological status against SARS-CoV-2 (nucleocapsid) was offered to all HCWs. All HCWs with positive SARS-CoV-2 serology were proposed to be included in a longitudinal medical and serological follow-up (anti-spike) for 7months.
resultsWe included 3062 HCWs; 256 (8.4%) were positive for anti-SARS-CoV-2 nucleocapsid IgG. Among them, early decrease in the anti-nucleocapsid antibody index was observed between the first (S1) and second (S2) serology samplings in 208 HCWs (84.2%). The initial anti-nucleocapsid IgG index seemed to be related to the HCWs' age. Seventy-four HCWs were included in the 7-month cohort study. Among them, 69 (90.5%) had detectable anti-spike IgG after 7months and 24 (32.4%) reported persistent symptoms consistent with post-acute COVID-19 syndrome diagnosis.
conclusionThe prevalence of serological positivity among HCWs was 6.7%. Infection should be followed by vaccination because of antibody decrease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.